Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Ivacaftor

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 10,593Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lupin Gets Tentative U.S. FDA Approval For Ivacaftor Oral Granules
    Lupin Gets Tentative U.S. FDA Approval For Ivacaftor Oral Granules

    10 Jan 2025

    // EXPRESSPHARMA

    https://www.expresspharma.in/lupin-secures-tentative-u-s-fda-approval-for-ivacaftor-oral-granules/

    EXPRESSPHARMA
    10 Jan 2025
    Share Share
    Vertex Announces FDA Approval for Trikafta to Non-F508del Variants
    Vertex Announces FDA Approval for Trikafta to Non-F508del Variants

    20 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241220045992/en

    BUSINESSWIRE
    20 Dec 2024
    Share Share
    Vertex inks long-term access deal for CF meds in Englan
    Vertex inks long-term access deal for CF meds in Englan

    22 Jun 2024

    // Fraiser Kansteiner FIERCE PHARMA

    https://www.fiercepharma.com/pharma/vertex-clinches-trikafta-and-other-cystic-fibrosis-drug-reimbursement-deal-england

    Fraiser Kansteiner FIERCE PHARMA
    22 Jun 2024
    Share Share
    Vertex Receives CHMP Positive Opinion for KALYDECO® for Cystic Fibrosis
    Vertex Receives CHMP Positive Opinion for KALYDECO® for Cystic Fibrosis

    23 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240222673931/en

    BUSINESSWIRE
    23 Feb 2024
    Share Share
    Vertex meets own cystic fibrosis record with next-gen treatment
    Vertex meets own cystic fibrosis record with next-gen treatment

    06 Feb 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/vertex-scores-phase-3-gold-after-next-gen-cystic-fibrosis-treatment-goes-against-trikafta

    FIERCE BIOTECH
    06 Feb 2024
    Share Share
    Vertex's sales of Trikafta hit $8.9B thanks to label expansion
    Vertex's sales of Trikafta hit $8.9B thanks to label expansion

    06 Feb 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/while-vertex-gears-next-generation-cf-treatment-trikafta-remains-formidable

    FIERCE PHARMA
    06 Feb 2024
    Share Share